Aclaris Therapeutics, Inc. (ACRS) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Aclaris Therapeutics, Inc. (ACRS) Bundle
Save time and improve accuracy with our (ACRS) DCF Calculator! Utilizing real Aclaris Therapeutics, Inc. data and customizable assumptions, this tool empowers you to forecast, analyze, and value (ACRS) like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.2 | 6.5 | 6.8 | 29.8 | 31.2 | 44.0 | 61.8 | 87.0 | 122.4 | 172.1 |
| Revenue Growth, % | 0 | 53.35 | 4.3 | 340.05 | 5.03 | 40.67 | 40.67 | 40.67 | 40.67 | 40.67 |
| EBITDA | -90.8 | -48.2 | -65.1 | -84.4 | -117.6 | -44.0 | -61.8 | -87.0 | -122.4 | -172.1 |
| EBITDA, % | -2148.97 | -743.52 | -962.28 | -283.53 | -376.22 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 1.6 | 1.3 | .9 | .8 | .9 | 6.8 | 9.5 | 13.4 | 18.9 | 26.5 |
| Depreciation, % | 37.52 | 20.43 | 13.65 | 2.68 | 2.76 | 15.41 | 15.41 | 15.41 | 15.41 | 15.41 |
| EBIT | -92.4 | -49.5 | -66.0 | -85.2 | -118.4 | -44.0 | -61.8 | -87.0 | -122.4 | -172.1 |
| EBIT, % | -2186.49 | -763.95 | -975.94 | -286.21 | -378.98 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 75.0 | 54.1 | 225.7 | 229.8 | 119.1 | 44.0 | 61.8 | 87.0 | 122.4 | 172.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .7 | .8 | .6 | .5 | .3 | 3.5 | 5.0 | 7.0 | 9.9 | 13.9 |
| Account Receivables, % | 16.65 | 11.91 | 9.21 | 1.63 | 0.95363 | 8.07 | 8.07 | 8.07 | 8.07 | 8.07 |
| Inventories | 5.0 | .0 | -34.2 | -12.2 | .0 | -3.6 | -5.1 | -7.2 | -10.1 | -14.2 |
| Inventories, % | 117.48 | 0 | -506.46 | -41.15 | 0 | -8.23 | -8.23 | -8.23 | -8.23 | -8.23 |
| Accounts Payable | 9.9 | 5.3 | 10.0 | 10.4 | 8.9 | 30.3 | 42.6 | 59.9 | 84.2 | 118.5 |
| Accounts Payable, % | 234.61 | 81.06 | 147.69 | 34.79 | 28.41 | 68.85 | 68.85 | 68.85 | 68.85 | 68.85 |
| Capital Expenditure | -1.6 | -.5 | -.3 | -.6 | -1.3 | -4.9 | -6.9 | -9.7 | -13.7 | -19.3 |
| Capital Expenditure, % | -38.16 | -6.99 | -4.56 | -2.03 | -4.19 | -11.19 | -11.19 | -11.19 | -11.19 | -11.19 |
| Tax Rate, % | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 | 0.41307 |
| EBITAT | -116.3 | -49.3 | -83.0 | -86.9 | -117.9 | -43.9 | -61.7 | -86.9 | -122.2 | -171.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -112.1 | -48.2 | -43.2 | -108.2 | -131.9 | -20.3 | -46.8 | -65.8 | -92.6 | -130.3 |
| WACC, % | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -292.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -133 | |||||||||
| Terminal Value | -3,917 | |||||||||
| Present Terminal Value | -3,012 | |||||||||
| Enterprise Value | -3,305 | |||||||||
| Net Debt | -39 | |||||||||
| Equity Value | -3,266 | |||||||||
| Diluted Shares Outstanding, MM | 70 | |||||||||
| Equity Value Per Share | -46.78 |
What You Will Get
- Real ACRS Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Aclaris Therapeutics' future performance.
- User-Friendly Interface: Designed for professionals while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life ACRS Financials: Pre-filled historical and projected data for Aclaris Therapeutics, Inc. (ACRS).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Aclaris's intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Aclaris's valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the prebuilt Excel template with Aclaris Therapeutics' data included.
- Step 2: Explore the pre-filled sheets and understand the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Aclaris Therapeutics' intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose This Calculator for Aclaris Therapeutics, Inc. (ACRS)?
- Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and industry consultants.
- Accurate Data: Aclaris Therapeutics' historical and projected financials are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth navigation through the process.
Who Should Use This Product?
- Investors: Evaluate Aclaris Therapeutics’ valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
- Startup Founders: Understand the valuation strategies of established biotech companies like Aclaris Therapeutics.
- Consultants: Provide expert valuation analyses and reports for client projects.
- Students and Educators: Utilize current data to learn and teach valuation practices in the biotech sector.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Aclaris Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models presenting intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Aclaris Therapeutics, Inc. (ACRS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions for easy result analysis.